Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in
Pharmacopedia is being built in public. Pages may be incomplete.About this site

Choose a table:


Medicines > generic : 2-FA or 2C-B or Guanfacine

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
None (1) · Intuniv (extended-release), Tenex (immediate-release) (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1)
classes:
2C-x series (1) · Amphetamine (1) · Phenethylamine (1) · Psychedelic (1) · Research material (1) · Stimulant (1) · [[:Category:ADHD medicines|ADHD medicine]] (1) · [[:Category:Alpha-2 adrenergic agonists|Alpha-2 adrenergic agonist]] (1) · [[:Category:Antihypertensives|Antihypertensive (historical)]] (1)
mechanism:
5-HT2A partial agonist (1) · Monoamine releasing agent (1) · '"`UNIQ--vote-00000019-QINU`"' Sedation and hypotension are the dose-limiting effects; gradual titration and bedtime or split dosing mitigate both. Abrupt discontinuation can precipitate rebound hypertension, particularly with long-standing use'"`UNIQ--ref-0000001A-QINU`"'. (1)
uses:
None (2) · '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (1)
starting dose:
None (2) · Intuniv ER 1 mg PO once daily; titrate by 1 mg/week as tolerated to clinical response (1)
preparations:
None (2) · Extended-release tablets 1, 2, 3, 4 mg (Intuniv); immediate-release tablets 1, 2 mg (Tenex) (1)
fda max:
None (2) · 7 mg/day in children and adolescents; weight-based ceiling (~0.12 mg/kg/day) applies in smaller patients (1)
routes:
None (1) · insufflated (1) · Oral (2) · PR (1)
onset:
None (1) · 45-75 min (oral) (1) · Gradual; full clinical effect over 2-4 weeks of titration (1)
duration:
None (1) · 4-8 h (1) · ~24 hours (ER formulation supports once-daily dosing) (1)
halflife:
None (1) · Not well characterized (1) · ~17-18 hours (Intuniv ER); ~17 hours (immediate-release)'"`UNIQ--ref-00000020-QINU`"' (1)
bioavailability:
None (1) · Not well characterized (1) · ~58% (extended-release); ~80% (immediate-release)'"`UNIQ--ref-00000021-QINU`"' (1)
pregnancy:
None (1) · Limited human data. Animal studies show fetal effects at maternally toxic doses; use only if benefits justify the potential risk.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)
legal:
None (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, which is a meaningful contrast to the psychostimulant alternatives for ADHD'"`UNIQ--ref-00000022-QINU`"' (1)

Showing below up to 3 results in range #1 to #3.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

2


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"